Myrbetriq

Overactive Bladder Syndrome, Neurogenic Detrusor Overactivity, Obesity
Treatment
2 FDA approvals
20 Active Studies for Myrbetriq

What is Myrbetriq

MirabegronThe Generic name of this drug
Treatment SummaryMirabegron is a medication used to treat urinary frequency and incontinence. It works by relaxing the bladder muscles, and is different from other similar medications because it doesn’t have the same side effects. Mirabegron was first approved by the FDA in 2012 and is also used in other countries. It can also be used in combination with other medications for more serious cases, and an extended-release granule formulation was recently approved for children with neurogenic detrusor overactivity.
Myrbetriqis the brand name
image of different drug pills on a surface
Myrbetriq Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Myrbetriq
Mirabegron
2012
8

Approved as Treatment by the FDA

Mirabegron, also known as Myrbetriq, is approved by the FDA for 2 uses which include Overactive Bladder Syndrome (OABS) and Overactive Bladder Syndrome .
Overactive Bladder Syndrome (OABS)
Used to treat Overactive Bladder Syndrome (OABS) in combination with Solifenacin
Overactive Bladder Syndrome
Used to treat Overactive Bladder Syndrome (OABS) in combination with Solifenacin

Effectiveness

How Myrbetriq Affects PatientsMirabegron works by making the bladder muscles relax, allowing it to hold more and reducing any urgency to urinate. However, it can raise both blood pressure and heart rate, so it should be used with caution in those with severe hypertension or other conditions where these increases could be dangerous. It should also be used with care in patients with bladder outlet obstruction, as it has been linked to urinary retention.
How Myrbetriq works in the bodyMirabegron is a medication that relaxes the muscles of the bladder. This increases the bladder's capacity, making it easier to hold in urine and reducing the feeling of needing to go often.

When to interrupt dosage

The prescribed dosage of Myrbetriq is contingent upon the recognized condition, including Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome and a weight of at least 35 kg. The measure of dosage alters, dependent upon the technique of delivery (e.g. Granule, for suspension, extended release - Oral or Tablet, extended release - Oral) as indicated in the table beneath.
Condition
Dosage
Administration
Overactive Bladder Syndrome
, 25.0 mg, 50.0 mg, 8.0 mg/mL
Oral, Tablet, extended release - Oral, , Tablet, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral
Neurogenic Detrusor Overactivity
, 25.0 mg, 50.0 mg, 8.0 mg/mL
Oral, Tablet, extended release - Oral, , Tablet, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral
Obesity
, 25.0 mg, 50.0 mg, 8.0 mg/mL
Oral, Tablet, extended release - Oral, , Tablet, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral

Warnings

Myrbetriq Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Mirabegron may interact with Pulse Frequency
There are 20 known major drug interactions with Myrbetriq.
Common Myrbetriq Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Mirabegron.
Axitinib
Major
The serum concentration of Axitinib can be increased when it is combined with Mirabegron.
Bendamustine
Major
The serum concentration of Bendamustine can be increased when it is combined with Mirabegron.
Binimetinib
Major
The serum concentration of Binimetinib can be increased when it is combined with Mirabegron.
Cabazitaxel
Major
The serum concentration of Cabazitaxel can be increased when it is combined with Mirabegron.
Myrbetriq Toxicity & Overdose RiskIf the recommended maximum dose of Diovan is exceeded (up to 400mg for healthy volunteers), the individual may experience palpitations and a faster heart rate. Long-term overdosing can produce similar symptoms and a rise in systolic blood pressure. If someone overdoses on Diovan, standard treatments should be administered alongside ECG monitoring.
image of a doctor in a lab doing drug, clinical research

Myrbetriq Novel Uses: Which Conditions Have a Clinical Trial Featuring Myrbetriq?

33 active clinical trials are examining the potential of Myrbetriq for treating Neurogenic Detrusor Overactivity, Pediatric Subjects with Weight at least 35 kg and Overactive Bladder Syndrome.
Condition
Clinical Trials
Trial Phases
Obesity
641 Actively Recruiting
Not Applicable, Phase 2, Phase 4, Phase 1, Early Phase 1, Phase 3
Overactive Bladder Syndrome
29 Actively Recruiting
Phase 3, Not Applicable, Phase 4, Phase 1, Phase 2
Neurogenic Detrusor Overactivity
3 Actively Recruiting
Phase 2, Phase 3, Phase 1

Myrbetriq Reviews: What are patients saying about Myrbetriq?

5Patient Review
4/20/2022
Myrbetriq for Overactive Bladder
When given oxybutynin alongside this medication, I saw the best results. No leakage or urgency. My blood pressure was already normal, but it increased slightly. However, it's nothing to worry about in comparison to the massive improvements in quality of life and confidence that these two medications have brought me.
5Patient Review
7/26/2022
Myrbetriq for Overactive Bladder
Myretig has been an amazing medication for me. After my hysterectomy, I developed OB and was constantly leaking. This medication has helped me to be dry most of the day and urinate normally.
3.7Patient Review
8/16/2020
Myrbetriq for Frequent Urination
Unfortunately, I experienced some pretty severe chest pains about ten days after using this medication. I ended up in atrial fibrillation and needed a pacemaker.
3.7Patient Review
6/21/2020
Myrbetriq for Needing to Urinate Immediately
I no longer have to wake up to use the restroom as frequently, but when I do have to go, it's an immediate emergency. Additionally, I don't care for the smell of my urine now and my back pains seem more intense.
3.3Patient Review
8/22/2022
Myrbetriq for Overactive Bladder
I experienced a lot of side effects from the medication, including nausea, dizziness, headaches, and elevated blood pressure. I'm not sure if the benefits were worth it.
3Patient Review
2/19/2020
Myrbetriq for Overactive Bladder
I've been using Myrbetriq for a little over three months now. It's helped somewhat, but I still feel the constant urge to urinate. Additionally, I've experienced dry eyes and lower back pain. I'm going to give it a few more weeks before trying Botox in the bladder.
2.7Patient Review
2/25/2022
Myrbetriq for Overactive Bladder
I lost half of my hair while using this medication, which was a huge and very unexpected side effect. It's been slowly growing back, but I'll never get back the volume or thickness that I had before.
2.3Patient Review
3/17/2022
Myrbetriq for Overactive Bladder
I had some really severe and uncomfortable side effects while taking this medication. I'm glad I did my own research and stopped before things got worse.
2Patient Review
10/18/2021
Myrbetriq for Needing to Urinate Immediately
I saw no difference after taking this medication for four weeks. It was a waste of money.
2Patient Review
2/12/2022
Myrbetriq for Frequent Urination
I've been taking the 50mg pill daily for a month now with no reduction in how many times I have to urinate at night.
2Patient Review
4/21/2022
Myrbetriq for Overactive Bladder
I have experienced some bleeding since starting this medication.
2Patient Review
1/17/2021
Myrbetriq for Overactive Bladder
I didn't have a good experience with this medication because of the severe side effects I experienced, like nausea and dizziness. My blood pressure also increased, which is not ideal for someone who already has low blood pressure.
2Patient Review
2/17/2021
Myrbetriq for Needing to Urinate Immediately
It's had some effect, but not as much as I would like given the price.
1.7Patient Review
7/16/2021
Myrbetriq for Overactive Bladder
I started having memory problems after only five days of taking this drug. I stopped immediately, but there has been no improvement. The only other possible explanations are that I had undiagnosed COVID, which can sometimes cause this side effect, or it was from a slight increase in my Moclobimide dose. But I have taken Moclobimide at that dose before without any problems, and I tested negative for Covid.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about myrbetriq

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Myrbetriq make you pee more?

"Myrbetriq can help children with NDO by increasing the capacity of their bladder and reducing the number of incontinence episodes."

Answered by AI

What is the side effects of Myrbetriq?

"The most common side effects of MYRBETRIQ are high blood pressure, nasopharyngitis, urinary tract infection, and headache."

Answered by AI

What is Myrbetriq used to treat?

"This medication is used to treat certain bladder problems including overactive bladder and neurogenic detrusor overactivity. Overactive bladder is a bladder storage problem while neurogenic detrusor overactivity is a bladder control condition caused by issues with the brain, spinal cord or nerves."

Answered by AI

What symptoms does Myrbetriq treat?

"The detrusor muscle is the muscle that contracts and relaxes to hold and release urine.

Myrbetriq may be prescribed to adults with OAB in order to treat urinary frequency, urgency, or incontinence. OAB is caused by the detrusor muscle in the bladder contracting too often or without warning. The detrusor muscle is the muscle that contracts and relaxes to hold and release urine."

Answered by AI

Clinical Trials for Myrbetriq

Image of Metabolic Kitchen and Children's Eating Behavior Lab in State College, United States.

Eating Behavior Assessment for Childhood Obesity

7 - 9
All Sexes
State College, PA
This study will explore how children's eating behaviors are connected to brain activity and body fat levels. Researchers are especially interested in a behavior pattern called the PACE phenotype, which includes how much children eat when offered large portions, how quickly they eat, their appetite traits, and their ability to control eating. The goal is to better understand why some children are more likely to gain weight than others. The study will include children between the ages of 7 and 9 and will follow them for one year. Researchers will use brain scans, lab-based meal observations, and questionnaires to study how children respond to food and how their eating patterns relate to body fat at the start of the study and one year later. The study will also look at how family background, parenting, and other factors might protect some children from gaining excess weight even if they show risky eating behaviors. Results may help identify which children are most at risk for obesity and guide future strategies for prevention.
Waitlist Available
Has No Placebo
Metabolic Kitchen and Children's Eating Behavior LabKathleen L Keller, Ph.D.
Image of Neighborhood Healthcare in Escondido, United States.

Cagrilintide + CagriSema for Childhood Obesity

8 - 18
All Sexes
Escondido, CA
This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to adolescents and adults) or placebo (a placebo looks like the treatment being tested, but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance. Participants who get semaglutide in the main study will not take part in the extension study. If participants take part in the extension study, they will get either CagriSema or cagrilintide in this part of the study. Like all drugs, the study drugs may have side effects. The total time participants will be in the main study is about 1 year and 6 months. If participants take part in the extension study, the total time is about 4 years and 10 months.
Phase 3
Waitlist Available
Neighborhood Healthcare (+30 Sites)Clinical Transparency (dept. 2834)Novo Nordisk A/S
Have you considered Myrbetriq clinical trials? We made a collection of clinical trials featuring Myrbetriq, we think they might fit your search criteria.Go to Trials
Image of University of Georgia in Athens, United States.

Cottonseed Oil for High Cholesterol

25 - 75
All Sexes
Athens, GA
Cardiovascular disease risk factors, including higher BMIs and poor cholesterol profiles, are on the rise and contribute to the United States' growing disease burden. Cottonseed oil (CSO) is found readily in the food supply, and the investigator's previous studies have demonstrated that incorporating CSO into the diet is sufficient to improve fasting and postprandial blood lipids and other markers of chronic disease risk in both healthy and at-risk populations. This study aims to examine the impact of intermittent CSO consumption at different doses (consumed three times per week (3x/wk)) on changes in fasting and postprandial lipid metabolism/blood lipids and markers of chronic disease risk. The specific aims are: \*Examine the impact of intermittent CSO consumption (3x/week) at two different doses on fasting and postprandial lipids. \*Examine the impact of intermittent CSO consumption (3x/week) at two different doses on other markers of chronic disease risk. Participants will be asked to: \*Consume provided meal replacement shakes and snacks 3 times per week for 56 days. \*Attend three bi-weekly (every other week) short visits for fasting blood draws, body measurements, and collection of the next two weeks' study materials. \*Attend two longer (5.5h) testing visits, which include eating a standardized breakfast meal and having blood drawn periodically before and after breakfast. Researchers will compare CSO-30, CSO-20, and Control groups (receiving no oil) to see if intermittent CSO consumption imparts the same health benefits as previously shown with daily doses of CSO.
Waitlist Available
Paid Trial
University of GeorgiaJamie Cooper, PhD
Image of UConn Health in Farmington, United States.

Digital Exercise Prescription Tool for Cardiovascular Disease

18 - 64
All Sexes
Farmington, CT
The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for physicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with cardiovascular disease (CVD) risk factors. The investigators will recruit 24 physicians from two local hospitals in CT, USA. Physicians will recruit two patients each (N=48) having CVD risk factors. Physicians will deliver a P3-EX exercise prescription (ExRx) to one of their patients (n=24) and the American College of Sports Medicine Physical Activity Vital Sign (ACSM-PAVS) ExRx to the other (n=24) in a random sequence crossover design. Physicians and patients will rate the feasibility and acceptability of each method using validated questionnaires. Patients will perform their prescribed ExRx for 12 weeks and complete a self-report exercise diary to monitor exercise adherence with virtual oversight from University of Connecticut (UConn) Graduate Research Assistants. Before and after the exercise intervention, the investigators will measure patient CVD risk factors and physical activity (PA) levels via accelerometry. The primary aim is to evaluate the feasibility and acceptability of P3-EX for physicians to use to prescribe exercise to patients with CVD risk factors, and the secondary aim is to explore the preliminary efficacy of P3-EX to improve patient CVD risk factors, PA levels, and exercise adherence. The investigators hypothesize P3-EX will be feasible for physicians to use to prescribe customized exercise routines for patients with CVD risk factors, and physicians and patients will be satisfied with P3-EX.
Waitlist Available
Has No Placebo
UConn Health (+2 Sites)Linda S Pescatello, PhD
Have you considered Myrbetriq clinical trials? We made a collection of clinical trials featuring Myrbetriq, we think they might fit your search criteria.Go to Trials
Have you considered Myrbetriq clinical trials? We made a collection of clinical trials featuring Myrbetriq, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security